Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.09)
# 484
Out of 5,065 analysts
494
Total ratings
48.22%
Success rate
13.15%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Assumes: Buy | $38 | $23.05 | +64.86% | 3 | Nov 17, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $232 → $258 | $169.80 | +51.94% | 27 | Nov 13, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $18.48 | +8.23% | 16 | Nov 11, 2025 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $5 → $4 | $3.94 | +1.52% | 15 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $19.61 | +129.47% | 27 | Oct 31, 2025 | |
| ARGX argenx SE | Maintains: Buy | $774 → $915 | $918.92 | -0.43% | 41 | Oct 31, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $16 | $2.08 | +669.23% | 27 | Oct 10, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $85.40 | -6.32% | 35 | Oct 8, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $1 | $1.88 | -46.81% | 18 | Sep 30, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $20.22 | -1.09% | 21 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $28.61 | +60.78% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $34 | $27.25 | +24.77% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $22.59 | +54.94% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.83 | +42.42% | 18 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $2.98 | +134.90% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $30 | $9.69 | +209.60% | 15 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $6.85 | +191.97% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $92.60 | +27.43% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $42.84 | +89.08% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $41.16 | +28.77% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.16 | +503.45% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $30.34 | +12.06% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $29.49 | -35.57% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.68 | +614.29% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.33 | +672.53% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.83 | +43,273.49% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.78 | +461.80% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $164.56 | +10.60% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.46 | +151.34% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $41.63 | -56.76% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $24.21 | -66.96% | 7 | Jun 11, 2019 |
Pacira BioSciences
Nov 17, 2025
Assumes: Buy
Price Target: $38
Current: $23.05
Upside: +64.86%
Praxis Precision Medicines
Nov 13, 2025
Maintains: Buy
Price Target: $232 → $258
Current: $169.80
Upside: +51.94%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $18.48
Upside: +8.23%
Minerva Neurosciences
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $3.94
Upside: +1.52%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $19.61
Upside: +129.47%
argenx SE
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $918.92
Upside: -0.43%
Cabaletta Bio
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.08
Upside: +669.23%
Protagonist Therapeutics
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $85.40
Upside: -6.32%
Outlook Therapeutics
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.88
Upside: -46.81%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $20.22
Upside: -1.09%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $28.61
Upside: +60.78%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $27.25
Upside: +24.77%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $22.59
Upside: +54.94%
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $9.83
Upside: +42.42%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $2.98
Upside: +134.90%
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $9.69
Upside: +209.60%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.85
Upside: +191.97%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $92.60
Upside: +27.43%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $42.84
Upside: +89.08%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $41.16
Upside: +28.77%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.16
Upside: +503.45%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $30.34
Upside: +12.06%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $29.49
Upside: -35.57%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.68
Upside: +614.29%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.33
Upside: +672.53%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.83
Upside: +43,273.49%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.78
Upside: +461.80%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $164.56
Upside: +10.60%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.46
Upside: +151.34%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $41.63
Upside: -56.76%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $24.21
Upside: -66.96%